Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

123 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V, Schmidt CE, Lennartz M, Höflmayer D, Hube-Magg C, Weidemann S, Fraune C, Büscheck F, Möller K, Bernreuther C, Simon R, Clauditz TS, Blessin NC, Bady E, Sauter G, Uhlig R, Steurer S, Minner S, Burandt E, Dum D, Marx AH, Krech T, Lebok P, Hinsch A, Jacobsen F. Reiswich V, et al. Among authors: buscheck f. Pathobiology. 2023;90(4):219-232. doi: 10.1159/000527382. Epub 2023 Jan 17. Pathobiology. 2023. PMID: 36649695 Free PMC article.
PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) for prevention of cardioembolic stroke in non-anticoagulation eligible atrial fibrillation patients: results from the European PLAATO study.
Bayard YL, Omran H, Neuzil P, Thuesen L, Pichler M, Rowland E, Ramondo A, Ruzyllo W, Budts W, Montalescot G, Brugada P, Serruys PW, Vahanian A, Piéchaud JF, Bartorelli A, Marco J, Probst P, Kuck KH, Ostermayer SH, Büscheck F, Fischer E, Leetz M, Sievert H. Bayard YL, et al. Among authors: buscheck f. EuroIntervention. 2010 Jun;6(2):220-6. EuroIntervention. 2010. PMID: 20562072 Clinical Trial.
Percutaneous devices for stroke prevention.
Bayard YL, Ostermayer SH, Hein R, Skowasch M, Büscheck F, Baranowski A, Heinisch C, Sievert H. Bayard YL, et al. Among authors: buscheck f. Cardiovasc Revasc Med. 2007 Jul-Sep;8(3):216-25. doi: 10.1016/j.carrev.2007.01.005. Cardiovasc Revasc Med. 2007. PMID: 17765654 Review.
Patent foramen ovale and left atrial appendage: new devices and methods for closure.
Hein R, Bayard Y, Taaffe M, Büscheck F, Ostermayer S, Billinger K, Reschke M, Trepels T, Lissmann-Jensen H, Lang K, Römer A, Wilson N, Sievert H. Hein R, et al. Among authors: buscheck f. Pediatr Cardiol. 2005 May-Jun;26(3):234-40. doi: 10.1007/s00246-005-1011-7. Pediatr Cardiol. 2005. PMID: 16132300
CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer.
Nienstedt JC, Gröbe A, Lebok P, Büscheck F, Clauditz T, Simon R, Heumann A, Sauter G, Moebius C, Münscher A, Knecht R, Blessmann M, Heiland M, Pflug C. Nienstedt JC, et al. Among authors: buscheck f. Clin Oral Investig. 2017 Jun;21(5):1503-1508. doi: 10.1007/s00784-016-1911-3. Epub 2016 Jul 21. Clin Oral Investig. 2017. PMID: 27444451
Up-regulation of mismatch repair genes MSH6, PMS2 and MLH1 parallels development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer.
Wilczak W, Rashed S, Hube-Magg C, Kluth M, Simon R, Büscheck F, Clauditz TS, Grupp K, Minner S, Tsourlakis MC, Möller-Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Izbicki JR, Huland H, Schlomm T, Steurer S, Krech T, Lebok P. Wilczak W, et al. Among authors: buscheck f. Carcinogenesis. 2017 Jan;38(1):19-27. doi: 10.1093/carcin/bgw116. Epub 2016 Nov 1. Carcinogenesis. 2017. PMID: 27803051
Deletion of 18q is a strong and independent prognostic feature in prostate cancer.
Kluth M, Graunke M, Möller-Koop C, Hube-Magg C, Minner S, Michl U, Graefen M, Huland H, Pompe R, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Büscheck F, Clauditz T, Wilczak W, Sauter G, Schlomm T, Simon R. Kluth M, et al. Among authors: buscheck f. Oncotarget. 2016 Dec 27;7(52):86339-86349. doi: 10.18632/oncotarget.13404. Oncotarget. 2016. PMID: 27861151 Free PMC article.
Deletion of 8p is an independent prognostic parameter in prostate cancer.
Kluth M, Amschler NN, Galal R, Möller-Koop C, Barrow P, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Steurer S, Krech T, Büscheck F, Clauditz TS, Beyer B, Wilczak W, Graefen M, Huland H, Minner S, Schlomm T, Sauter G, Simon R. Kluth M, et al. Among authors: buscheck f. Oncotarget. 2017 Jan 3;8(1):379-392. doi: 10.18632/oncotarget.13425. Oncotarget. 2017. PMID: 27880722 Free PMC article.
123 results